A Single Arm Phase II Study of Neoadjuvant Therapy Using Irinotecan Bead in Patients With Resectable Liver Metastases From Colorectal Cancer.

Trial Profile

A Single Arm Phase II Study of Neoadjuvant Therapy Using Irinotecan Bead in Patients With Resectable Liver Metastases From Colorectal Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2015

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms PARAGON-II
  • Sponsors Biocompatibles International
  • Most Recent Events

    • 29 May 2015 Primary endpoint has been met (tumour resectability at surgery) according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top